Nektar Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
Nektar Therapeutics income statement - Annual data in billions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.100.090.090.100.150.111.19
Cost of Revenue0.030.030.020.020.020.020.02
Gross Profit0.070.060.070.080.130.091.17
Operating Expenses
Research & Development0.120.110.220.400.410.430.40
Selling, General & Administrative0.080.080.090.120.100.100.08
Operating Expenses0.200.190.310.520.510.530.48
Operating Income-0.13-0.14-0.24-0.45-0.43-0.440.69
Other Income/Expense
Interest Income0.010.020.010.000.020.000.04
Interest Expense-0.030.030.03-0.05-0.040.000.04
Other Income/Expense0.00-0.13-0.100.070.01-0.020.00
Income
Income Before Tax-0.12-0.28-0.36-0.52-0.44-0.440.68
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-0.12-0.28-0.37-0.52-0.44-0.440.68
Net Income - Continuous Operations-0.12-0.28-0.37-0.520.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-0.13-0.24-0.32-0.46-0.39-0.410.74
EBIT-0.13-0.25-0.34-0.48-0.41-0.420.73
Depreciation & Amortization0.000.010.010.010.010.010.00
Earnings Per Share
Basic EPS-9.00-22.00-30.00-3.00-2.00-3.004.00
Diluted EPS-9.00-22.00-30.00-3.00-2.00-3.004.00
Basic Shares Outstanding0.010.010.010.180.180.170.17
Diluted Shares Outstanding0.010.010.010.180.180.170.18